[{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint Neuro \/ UCB Pharma S.A"}]

Find Clinical Drug Pipeline Developments & Deals by ClearPoint Neuro

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Europe
                          Not Confirmed
                          ISPE Europe
                          Not Confirmed

                          Details : Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 24, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : UCB Pharma S.A

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank